NMN for Desk Workers: What Sitting Does to NAD+

Seventy-four per cent of British 46-year-olds sit more than eight hours a day

That figure comes from thigh-worn activity monitors on 5,300 people in the 1970 British Cohort Study. Not a questionnaire. Seven days of accelerometry, published in the American Journal of Epidemiology.

A quarter of that sitting arrived in unbroken blocks of an hour or more. When Americans were asked to estimate their own sitting in the national survey, only 26% said they passed eight hours. People underestimate this badly, and you probably do too.

So the useful question for a desk-based reader is not whether you exercise. You may well train five times a week. The variable is the other nine waking hours, and what they do to the machinery that makes your NAD+.

Two weeks of low stepping cost 17% of insulin sensitivity

Ten healthy young men in Copenhagen dropped from 10,501 steps a day to 1,344 for a fortnight. Diet unchanged. No structured exercise before or during.

Glucose infusion rate during a hyperinsulinaemic-euglycaemic clamp — the reference method for insulin sensitivity — fell 17%, from 6.29 to 5.22 mg/kg/min. Liver glucose output did not move. The loss was peripheral, in muscle.

Two other things fell in the same fortnight. VO2 max dropped 7.2%. Leg lean mass dropped 2.8%, which nobody expected from two weeks of merely walking less.

Nobody sits at 1,344 steps for a fortnight on purpose. But a bad week — deadline, flight, illness — lands close to it, and the damage starts fast.

Sitting is an NAD+ problem because of one enzyme

Most of your NAD+ is not built from scratch. It is recycled, through the salvage pathway, and the rate-limiting step is an enzyme called NAMPT — nicotinamide phosphoribosyltransferase.

NAMPT abundance in human skeletal muscle falls with age. It also tracks with fitness. In a 2019 study, VO2 peak was the single best predictor of how much NAMPT a person's muscle carried.

Twelve weeks of training changed it. Aerobic training raised NAMPT by 12% in young subjects and 28% in older ones. Resistance training raised it 25% and 30%. That was enough to abolish the age difference entirely.

Read that in reverse and you have the desk worker's problem. NMN supplies raw material to the salvage pathway. Training supplies the enzyme that runs it. Sitting quietly lowers the second, and no capsule fixes that. There is more on the underlying chemistry in our piece on what NAD+ actually is.

The one NMN trial that matches a sedentary body

Most NMN trials enrol healthy, reasonably active volunteers. One did not, and it is the most relevant trial in the literature for this question.

Washington University randomised 25 postmenopausal women with prediabetes, overweight or obese, to 250 mg NMN or placebo for ten weeks. They used the clamp, the same reference method as the Copenhagen study.

Twenty-five people. One site. One narrow phenotype. It is a genuine positive result in exactly the metabolic state that prolonged sitting nudges you towards — and it has not been replicated.

Pool every trial and the metabolic effect disappears

A 2024 meta-analysis in Current Diabetes Reports gathered eight randomised trials, 342 middle-aged and older adults, doses from 250 to 2,000 mg a day for two to twelve weeks.

That is the honest shape of this evidence. NAD+ in blood goes up, dose-dependently, every time anyone measures it. Downstream metabolic markers do not follow. If you want to know where your own glucose control sits, an HbA1c result tells you more than any supplement label.

The physical function signal is real but thin

Eighty adults aged 40 to 65 were randomised to placebo or 300, 600 or 900 mg NMN for 60 days. Blood NAD+ rose dose-dependently, highest at 600 and 900 mg.

Six-minute walk distance was significantly greater than placebo in all three NMN arms at both day 30 and day 60, with the longest distances at 600 and 900 mg. Roughly twenty people per arm, so treat it as a lead rather than a conclusion.

Two other trials temper it. A 12-week Japanese trial of 250 mg in 36 healthy middle-aged adults raised NAD+ metabolites but found no significant difference in arterial stiffness overall. And when 12 men aged 70 to 80 took 1 g of nicotinamide riboside for 21 days, muscle NAD+ metabolites rose without any change in mitochondrial bioenergetics.

Getting the molecule into the tissue is not the hard part. Getting the tissue to do something different with it is.

Three minutes every thirty minutes beats anything in a capsule

Twenty-four inactive adults with type 2 diabetes, mean age 62, sat through three separate eight-hour days. One uninterrupted. One with three minutes of light treadmill walking every 30 minutes. One with three minutes of half-squats, calf raises, gluteal contractions and knee raises, done on the spot.

Seven-hour glucose area under the curve fell 39% on average. Insulin fell 36-37%, C-peptide 27-30%. The body-weight movements also cut the triglyceride response by 40%, which the walking did not.

No supplement trial in this field has produced an effect of that size on that timescale.

What a desk-based day should actually look like

The UK Chief Medical Officers' 2019 guidelines are explicit: minimise sedentary time, and break up long periods with at least light activity. They give no numeric ceiling on sitting, because the evidence does not support one.

The harmonised analysis of more than a million people found that roughly 60-75 minutes a day of moderate activity removed the mortality association with high sitting. That is a large dose, four to five times the UK weekly minimum, and it still did not fully offset high television time.

So the practical stack, in order of evidence:

• Interrupt every 30 minutes. Three minutes. Walk to the kettle, or do twenty squats and twenty calf raises at the desk.
• Protect the training. Sixty minutes of moderate activity a day is the figure that made sitting look harmless in the epidemiology.
• Watch the long blocks, not the total. A quarter of British mid-life sitting comes in hours-long stretches, and that pattern is the one linked to worse markers.
• Put the hardest interruption after lunch, when the glucose excursion is largest.

If the sitting is on a bike instead of a chair, the calculus changes — we covered that in NMN for cyclists.

What to measure, and what not to bother measuring

Skip the NAD+ blood test. Every trial agrees that oral NMN raises it, so a high result tells you the capsule dissolved. It does not tell you anything about your muscle, and the Copenhagen and Birmingham data both show the two can move independently.

Four numbers are worth tracking instead, and three of them are free.

Daily step count is the first. The Copenhagen men lost 17% of their insulin sensitivity moving from roughly 10,500 steps to 1,344. You want to know which end of that range a normal Tuesday puts you on.

Longest unbroken sitting bout is the second. Total hours matter less than whether they arrive in ninety-minute blocks. Most phones will tell you; a repeating 30-minute timer fixes it.

The third is fasting insulin, which you can ask a GP for alongside glucose. Together they give HOMA-IR, the crude index of insulin resistance that the NMN meta-analyses used as an outcome. It moves earlier than HbA1c does.

The fourth is an estimated VO2 max from a watch. It is imprecise, roughly ±10%, but it is the variable that predicted muscle NAMPT better than age did. A number drifting down over two years is telling you about your salvage capacity.

Where NMN fits for a desk worker

It fits after the movement, not instead of it. Anyone selling you NMN as a fix for eight hours in a chair is selling you the wrong end of the mechanism.

What can be said fairly: NMN raises blood NAD+ at 250-900 mg a day, consistently, across every trial that measured it. One 25-person trial in a sedentary, prediabetic, postmenopausal group found better muscle insulin sensitivity. One 80-person trial found more walking distance. The pooled glucose and lipid data are null, and we would rather you heard that from us.

If you want to try it, 250-500 mg a day with food is the range the positive trials used, and our dosage guide sets out the reasoning. It sits alongside trans-resveratrol in our NMN + Resveratrol formula.

Then get up every half hour. That part is not in doubt.

References

1. Hamer M, Stamatakis E, Chastin S, Pearson N, Brown M, Gilbert E, Sullivan A (2020). "Feasibility of measuring sedentary time with thigh-worn accelerometry, and sociodemographic correlates: the 1970 British Cohort Study." American Journal of Epidemiology. doi:10.1093/aje/kwaa047
2. Krogh-Madsen R, et al. (2010). "A 2-wk reduction of ambulatory activity attenuates peripheral insulin sensitivity." Journal of Applied Physiology. doi:10.1152/japplphysiol.00977.2009
3. de Guia RM, et al. (2019). "Aerobic and resistance exercise training reverses age-dependent decline in NAD+ salvage capacity in human skeletal muscle." Physiological Reports, 7(12), e14139. PMID 31207144
4. Dempsey PC, Larsen RN, Sethi P, et al. (2016). "Benefits for Type 2 Diabetes of Interrupting Prolonged Sitting With Brief Bouts of Light Walking or Simple Resistance Activities." Diabetes Care, 39(6), 964-972. doi:10.2337/dc15-2336
5. Yoshino M, Yoshino J, Kayser BD, et al. (2021). "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, 372(6547), 1224-1229. PMID 33888596
6. Chen F, Zhou D, Kong APS, Yim NT, Dai S, Chen YN, Hui LL (2024). "Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials." Current Diabetes Reports. doi:10.1007/s11892-024-01557-z. PMID 39531138
7. "Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials" (2024). Critical Reviews in Food Science and Nutrition. doi:10.1080/10408398.2024.2387324. PMID 39116016
8. Yi L, et al. (2023). "The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial." GeroScience, 45(1), 29-43. PMID 36482258
9. Katayoshi T, et al. (2023). "Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial." Scientific Reports, 13, 2786.
10. Elhassan YS, Kluckova K, Fletcher RS, et al. (2019). "Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures." Cell Reports, 28(7), 1717-1728. PMID 31412242
11. Ekelund U, Steene-Johannessen J, Brown WJ, et al. (2016). "Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women." The Lancet, 388(10051), 1302-1310.
12. UK Chief Medical Officers (2019). "UK Chief Medical Officers' Physical Activity Guidelines." Department of Health and Social Care, GOV.UK.

NMN + Resveratrol, with the evidence stated plainly

Third-party tested trans-resveratrol and NMN, made in the UK. We publish what the trials found, including the trials that found nothing. Read the page before you buy.

See NMN + Resveratrol →